{"entity":{"id":"nct04849364","kind":"trial","name":"PERSEVERE: genomically directed post-neoadjuvant residual TNBC","aka":[],"tldr":"This study assigned extra treatment after surgery using blood and tumour tests. It stopped and is no longer an access route.","summary":"Registry status terminated, last updated 2025-05-31. Enrollment is 52 actual. Residual early TNBC after neoadjuvant therapy and definitive resection. The ctDNA-enriched, genomically directed platform included talazoparib/capecitabine and inavolisib/capecitabine strategies, with pembrolizumab rules differing by assigned arm. The registry states termination for a funder decision; that administrative reason is not an efficacy result.","status":"withdrawn","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT04849364","url":"https://clinicaltrials.gov/study/NCT04849364"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["talazoparib","capecitabine","inavolisib","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04849364","phase":"2","setting":"Residual early TNBC after neoadjuvant therapy and definitive resection","sponsor":"Bryan Schneider, MD","started":"2021-08-24","startedType":"actual","enrolled":52,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04849364/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/"}]}}